Please provide your email address to receive an email when new articles are posted on . The FDA granted 510(k) clearance for the iStent infinite trabecular micro-bypass system to reduce IOP as a stand ...
ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal ...
Glaukos has secured European Union Medical Device Regulation (EU-MDR) certification for its iStent infinite, along with other micro-invasive glaucoma surgery (MIGS) technologies, including the iStent ...
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal ...
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today ...
Novel Three-Stent Injectable System Designed to Provide Foundational, 24/7 IOP Control ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and ...
ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback